Transforming Diabetes Care Through Artificial Intelligence: The Future Is Here
- PMID: 30256722
- PMCID: PMC6555175
- DOI: 10.1089/pop.2018.0129
Transforming Diabetes Care Through Artificial Intelligence: The Future Is Here
Abstract
An estimated 425 million people globally have diabetes, accounting for 12% of the world's health expenditures, and yet 1 in 2 persons remain undiagnosed and untreated. Applications of artificial intelligence (AI) and cognitive computing offer promise in diabetes care. The purpose of this article is to better understand what AI advances may be relevant today to persons with diabetes (PWDs), their clinicians, family, and caregivers. The authors conducted a predefined, online PubMed search of publicly available sources of information from 2009 onward using the search terms "diabetes" and "artificial intelligence." The study included clinically-relevant, high-impact articles, and excluded articles whose purpose was technical in nature. A total of 450 published diabetes and AI articles met the inclusion criteria. The studies represent a diverse and complex set of innovative approaches that aim to transform diabetes care in 4 main areas: automated retinal screening, clinical decision support, predictive population risk stratification, and patient self-management tools. Many of these new AI-powered retinal imaging systems, predictive modeling programs, glucose sensors, insulin pumps, smartphone applications, and other decision-support aids are on the market today with more on the way. AI applications have the potential to transform diabetes care and help millions of PWDs to achieve better blood glucose control, reduce hypoglycemic episodes, and reduce diabetes comorbidities and complications. AI applications offer greater accuracy, efficiency, ease of use, and satisfaction for PWDs, their clinicians, family, and caregivers.
Keywords: artificial intelligence; artificial pancreas; cognitive computing; diabetes care; glucose monitoring; retinal imaging.
Conflict of interest statement
Drs. Dankwa-Mullan, Park, Snowdon, and Rhee declare that there are no conflicts of interest. Drs. Rivo and Sepulveda received consulting fees from IBM Watson Health during the conduct of the study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The views expressed in this article are the authors' own and not an official position of IBM.
References
-
- International Diabetes Federation (IDF). IDF diabetes atlas, 7th edition. Brussels, Belgium: International Diabetes Federation, 2015
-
- Liu J, Wang R, Ganz ML, Paprocki Y, Schneider D, Weatherall J. The burden of severe hypoglycemia in type 2 diabetes. Curr Med Res Opin 2018;34:179–186 - PubMed
-
- Centers for Disease Control and Prevention. Estimates of diabetes and its burden in the United States. Washington, DC: US Department of Health and Human Services, 2017:1–20
-
- The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986 - PubMed
-
- Latts L. ADA/IBM Watson Health Study (N>300,000) finds that nearly 60% of people with T2D discontinue therapy after one year. Presented at: American Diabetes Association 78th Scientific Session, June 22–26, 2018, Orlando, FL
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous